Canadian Association for Population Therapeutics

Association Canadienne pour la thérapeutique des populations

Facts, Figures, and the Art of Health Care Decision-Making:
linking knowledge generation to health outcomes

PROGRAM

MARCH 28–30, 2010 | TORONTO, ONTARIO
THE FOUR SEASONS HOTEL
CAPT MISSION & VISION

The CAPT Mission is to advance population-based research of therapeutic interventions to improve the health outcomes of Canadians by:

- Bringing together diverse perspectives
- Facilitating open exchange of ideas and collaboration, and
- Influencing policy and practice

The CAPT Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice to optimize health outcomes.

CAPT 2010 SCIENTIFIC PLANNING COMMITTEE:

Larry Lynd, University of British Columbia (Co-Chair)
Carlo Marra, University of British Columbia (Co-Chair)
Michael Iskedjian, PharmIdeas
Lori-Jean Manness, Merck
Nicole Mittmann, Health Outcomes & PharmacoEconomics Research Centre
Nancy Risebrough, Oxford Outcomes
Angela Rocchi, Axia Research

CAPT 2010 LOCAL ORGANIZING COMMITTEE:

Jackie Gladman, i3 Innovus (Chair)
Alina Ciobanu, AstraZeneca
Anna Liovas, AstraZeneca
Michael Paterson, Institute for Clinical Evaluative Sciences
Laurene Redding, Takeda Canada Inc.

www.capt-actp.com
Message from the President

Welcome to the 2010 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference! You are joining a wide diversity of academic researchers, federal and provincial policy-makers, pharmaceutical industry representatives and other experts in an open exchange of ideas and collaboration to advance population-based research of therapeutic interventions.

The past year has been an interesting one for CAPT as Board members continued the Strategic Planning Initiative. You will hear more about the actions coming from this initiative at the conference. Over the next few days, enjoy meeting and listening to Canadian and international experts, reviewing the posters, catching up with friends and colleagues, making new contacts, and attending an exciting social event at the Royal Ontario Museum.

Nigel Rawson
CAPT President

CAPT 2010 Conference Overview

Welcome to the 2010 CAPT/ACTP conference! The title of this year’s conference, “Facts, Figures, and the Art of Health Care Decision-Making: linking knowledge generation to health outcomes” speaks to the need to translate the results from rigorous scientific investigation to health policy and decision-making. The Program Committee offers its sincere thanks to the sponsors who have made this conference possible.

The mission of CAPT/ACTP is to advance population-based research of therapeutic interventions to improve the health of Canadians by bringing together diverse perspectives, facilitating open exchange of ideas and collaboration, and influencing policy and practice. The Scientific Committee has designed the conference program to achieve this mission by inviting a wide variety of keynote speakers and panelists, by including more panel sessions than in previous conferences, and by balancing sessions in pharmacoepidemiology and health economics with others in health policy. In addition, we have many exciting contributed presentations and posters. We encourage you to maximize your opportunities for interaction and exchange of ideas throughout the three days with both old and new colleagues and friends, and hope that you enjoy the conference.

Carlo Marra & Larry Lynd
Co-Chairs, Scientific Committee
“Facts, Figures, and the Art of Health Care Decision-Making: linking knowledge generation to health outcomes”

Sunday, March 28th, 2010

** All Poster Presentations will be displayed in the Regency Ballroom West from 12:00 h Sunday until Monday at 17:30 h **

08:00 – 17:00 Registration (Regency Foyer)

Pre-Conference Symposium
Location: Regency Ballroom

09:00 – 12:00 CIHR’s Institute of Gender and Health Pre-Conference Symposium
Advancing Population-Based Research on Therapeutic Interventions by Accounting for Sex and Gender (Pre-Registration Required)

Speakers:
Steve Morgan, Associate Professor, School of Population and Public Health and Associate Director, Centre for Health Services and Policy Research, University of British Columbia, Vancouver
Judith Soon, Assistant Professor, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver
Emma Spreekmeester, Drug Reviewer, Bureau of Metabolism, Oncology and Reproductive Sciences, Health Canada Therapeutic Products Directorate, Ottawa

12:00 – 13:00 Hot Lunch & Contributed Poster Presentations
Location: Regency Foyer & Regency Ballroom West
(All conference registrants welcome)

Conference Commencement
Location: Regency Ballroom

13:00 – 13:15 Opening Remarks & Welcome
Nigel Rawson, GlaxoSmithKline Inc. and President, Canadian Association for Population Therapeutics

13:15 – 15:45 Health Policy Symposium (Sponsored by Merck)
Future pharmascape: the evolving pharmaceutical environment and implications for research, policy and health outcomes

Introduction and Opening Remarks
Lorne Tyrrell (Chair), CIHR/GSK Chair in Virology, University of Alberta and Board Chair, Institute of Health Economics, Edmonton
Sunday, March 28th, 2010

Comparative Effectiveness Research and Personalized Medicine: Implications for the Future Pharmascape
Clifford Goodman, Vice-President, The Lewin Group, Falls Church, Virginia

Coping with a paucity of data: An evaluation framework for rare diseases
Chaim Bell, Assistant Professor of Medicine and Health Policy, Management & Evaluation, University of Toronto, Toronto

Balancing Evidence and Access for new Cancer Agents
Terrence Sullivan, President and CEO, Cancer Care Ontario, Toronto

Access and Innovation: A Private Payer’s Perspective
Amanda Ung, Product Director, Pharmaceutical Benefits, Sun Life Financial, Toronto

15:45 – 16:15
Break & Contributed Poster Presentations
Location: Regency Foyer & Regency Ballroom West

16:15 – 17:30
Contributed Oral Presentations
Topics in Decision Making
Chair: Angela Rocchi, Axia Research

Ethnic disparities in prescription drug use: evidence from British Columbia
S Morgan, University of British Columbia (Abstract 10)

Surrogate outcomes in HTA decision making
R Modha, Heron Evidence Development Ltd. (Abstract 13)

Differences in EuroQol Five Dimension (EQ-5D) and Health Utilities Index 3 (HUI3) derived utility scores in an HIV population
P Isogai, HOPE Research Centre, Sunnybrook Health Sciences Centre (Abstract 7)

Seniors presenting to the Emergency Department after a fall: costs and consequences
JC Woolcott, University of British Columbia (Abstract 12)

Cost-effectiveness analysis of thiopurine methyltransferase testing to guide mercaptopurine starting doses in pediatric patients with acute lymphoblastic leukemia
JR Donnan, Newfoundland and Labrador Centre for Health Information (Abstract 6)
**Sunday, March 28th, 2010**

17:30 – 19:30  Reception & Contributed Poster Presentations  
(Sponsored by AstraZeneca Canada Inc.)  
Location:  Regency Foyer & Regency Ballroom West

**Monday, March 29th, 2010**

07:30 – 17:00  Registration (Regency Foyer)  
07:30 – 08:30  Breakfast  

Location:  Regency Ballroom

08:30 – 10:00  Vaccine / H1N1 symposium  
Policy/Epidemiology/Media lessons learned  
(Sponsored by GlaxoSmithKline Inc.)  
Chair:  Nigel Rawson, GlaxoSmithKline Inc.

**Speakers:**

**Epidemiology challenges in pandemic response**  
Allison McGeer, Professor, Mount Sinai Hospital, Toronto

**Ethical challenges in pandemic response**  
Cécile Bensimon, Post-doctoral Fellow, Joint Centre for Bioethics, University of Toronto, Toronto

**Media lessons learned in pandemic response**  
Don Low, Microbiologist-in-Chief, Mount Sinai Hospital, Toronto

10:00 – 10:30  Break & Contributed Poster Presentations  
Location:  Regency Foyer & Regency Ballroom West

10:30 – 12:00  Concurrent Sessions – Contributed Oral Presentations

**Concurrent Session 1:**  
Pharmacoepidemiology  
Location:  Regency Ballroom East

Chair:  Nancy Risebrough, Oxford Outcomes

**Rheumatoid arthritis and serious infections: a nested case-control study from the Ontario Biologics Research Initiative (OBRI)**  
S Bernatsky, McGill University (Abstract 11)
Monday, March 29th, 2010

Under-use of disease-modifying anti-rheumatic drugs for seniors with early rheumatoid arthritis: a population based study from the Ontario Biologics Research Initiative (OBRI)
C Bombardier, University of Toronto (Abstract 15)

Antipsychotic-induced cerebrovascular events in the elderly residents of Manitoba: a population-based cohort study
I Vasilyeva, University of Manitoba (Abstract 3)

Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors
SM Cadarette, University of Toronto, Brigham and Women’s Hospital, Harvard Medical School (Abstract 1)

Are we treating wheeze with bug killer?
C Marra, University of British Columbia (Abstract 4)

Effectiveness of antihypertensive agents in the secondary prevention of vascular events among patients with ischemic stroke – a nested case-control study
S Perreault, University of Montreal (Abstract 8)

Concurrent Session 2:
Novel Approaches to outcomes research, epidemiology, and decision-making
Location: Regency Ballroom Centre

Chair: Nicole Mittmann, HOPE Research Centre

An open-source, interactive model to assess the outcomes and economics of diabetes interventions
J Hornberger, Stanford University and Cedar Associates LLC (Abstract 2)

The importance of adjusting for potential confounders when combining evidence from randomised and non-randomised studies: a Bayesian hierarchical model
CE McCarron, McMaster University and PATH Research Institute (Abstract 14)

Use and misuse of IV pantoprazole in paediatric inpatients
E Lau, Hospital for Sick Children (Abstract 16)

Electronic vascular risk decision support: COMPETE III randomized trial
AM Holbrook, McMaster University (Abstract 9)

Using GIS maps to interpret patterns of contraceptive use among youth across British Columbia
P Raj, University of British Columbia (Abstract 17)
Monday, March 29th, 2010

Confounding and participation effect in a primary care cluster randomised controlled trial on dyslipidemia prescribing practices of physicians
L Lalonde, University of Montreal (Abstract 5)

12:00 – 13:30  Lunch (Sponsored by Eli Lilly Canada Inc.) & CAPT Annual General Meeting
All conference attendees are encouraged to participate.

13:30 – 15:00  New Methodologic Frontiers – Pharmacoepidemiology and Pharmacoeconomics
Chair: Carlo Marra, University of British Columbia
Speakers:

Frontiers in Pharmacoepidemiology
Sebastian Schneeweiss, Associate Professor, Brigham and Women’s Hospital / Harvard Medical School, Boston

Frontiers in Pharmacoeconomics
Murray Krahn, Senior Scientist, University of Toronto, Toronto

15:00 – 15:30  Break & Contributed Poster Presentations

15:30 – 17:30  Observational vs. experimental evidence to inform policy
The RCT vs observational study debate (Sponsored by SanofiAventis)
Moderator:
Robert Peterson, Executive Director, Drug Safety and Effectiveness Network, CIHR, Ottawa
Speakers:
Ken Bassett, Professor, University of British Columbia, Vancouver
David Juurlink, Associate Professor, Sunnybrook Health Sciences Centre, Toronto

18:30 – 21:00  CAPT Social & Networking Event (Ticket Required)
(Doors Open at 18:15)
Location: Royal Ontario Museum
(Sponsored by Takeda Canada, Inc.)
Speaker:
Ms. Helen Stevenson, Ontario Public Drug Programs, Toronto
Tuesday, March 30th, 2010

07:30 – 12:30  Registration (Regency Foyer)

07:30 – 08:30  Breakfast

08:30 – 10:00  Novel assessment frameworks to improve decision-making (Sponsored by Amgen)
Chair: Frances Hall, Health Canada

Speakers:
The Economics of Evaluating New Technologies
Tomas Philipson, Professor, University of Chicago, Chicago

Difficult Decision-Making at the User Interface: Why the Traditional Approach Doesn’t Work
Janet Martin, Assistant Professor, London Health Sciences Centre, London, ON

10:00 – 10:30  Break

10:30 – 11:45  Hot Topics in the Canadian Environment
Chair: Bonnie Cochrane, NL Centre for Health Information

1. Update on the Canadian Drug Safety and Effectiveness Network Initiative
   Robert Peterson, Executive Director, Drug Safety and Effectiveness Network, CIHR, Ottawa

2. Quantitative benefit-risk analysis in regulatory decision-making
   Larry Lynd, Associate Professor, University of British Columbia, Vancouver

11:45 – 12:00  CAPT Awards Ceremony / Conference Close
Angela Rocchi, Axia Research and President-Elect, Canadian Association for Population Therapeutics

12:00 – 12:30  Buffet Lunch
(Open to all conference registrants)
Tuesday, March 30th, 2010

12:30 – 14:30   Pfizer Canada Satellite Symposium (Pre-Registration Required)
Assessing the value of new therapies: where do we go from here?

Objectives of the symposium:
1) Share and exchange diverse perspectives on the current health technology assessment (HTA) processes and frameworks
2) Describe and discuss the challenges and strengths with the current HTA framework
3) Debate potential solutions and new approaches to improve the HTA framework for the medicines of the future

Chair: Scott Gavura, Director Provincial Drug Reimbursement Programs, Cancer Care Ontario

Panelists:

Amir Attaran, Canada Research Chair in Law, Population Health and Global Development Policy, Faculties of Law and Medicine; University of Ottawa; providing the legal perspective

Durhane Wong-Rieger, Chair, Consumer Advocare Network; providing the patient perspective

Jens Grueger, VP Global, Market Access, Pfizer; providing the Industry perspective

Margaret Somerville, Founding Director, McGill Centre for Medicine, Ethics and Law; providing the ethical perspective

Mona Sabharwal, Senior Manager Drug Benefits Management, Ontario Public Drug Programs; providing the payer perspective
ORAL PRESENTATIONS

(Note: Presenting Authors are underlined)

1  
Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA  
Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors

2  
Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J  
An open-source, interactive model to assess the outcomes and economics of diabetes interventions

3  
Vasilyeva I, Alessi-Severini S, Biscontri RG, Metge C, Collins DM, Enns MW  
Antipsychotic-induced cerebrovascular events in the elderly residents of Manitoba: a population-based cohort study

4 – ENCORE PRESENTATION  
Marra C, Marra F, Richardson K, Lynd L, FitzGerald JM  
Are we treating wheeze with bug killer?

5  
Confounding and participation effect in a primary care cluster randomised controlled trial on dyslipidemia prescribing practices of physicians

6  
Donnan JR, Ungar WJ, Mathews M, Rahman P  
Cost-effectiveness analysis of thiopurine methyltransferase testing to guide mercaptopurine starting doses in pediatric patients with acute lymphoblastic leukemia

7  
Differences in EuroQol Five Dimension (EQ-5D) and Health Utilities Index 3 (HUI3) derived utility scores in an HIV population

8  
Perreault S, Côté R, Dragomir A  
Effectiveness of antihypertensive agents in the secondary prevention of vascular events among patients with ischemic stroke – a nested case-control study

9  
Holbrook AM, Pullenayegum E, Thabane L, Keshavjee K, Chan D, Dolovich L, Troyan S, Foster G  
Electronic vascular risk decision support: COMPETE III randomized trial

10  
Morgan S, Hanley G, Cunningham C, Quan H  
Ethnic disparities in prescription drug use: evidence from British Columbia

11  
Bernatsky S, Paterson M, Pope J, Widdifield J, Thorne C, Cividino A, Bombardier C  
Rheumatoid arthritis and serious infections: a nested case-control study from the Ontario Biologics Research Initiative (OBRI)
12 Woolcott JC, Khan KM, Anis AH, Marra CA **Seniors presenting to the Emergency Department after a fall: costs and consequences**

13 Sedelnikova M, Modha R, Lock K, Howard P **Surrogate outcomes in HTA decision making**

14 McCarron CE, Pullenayegum EM, Thabane L, Goeree R, Tarride JE **The importance of adjusting for potential confounders when combining evidence from randomised and non-randomised studies: a Bayesian hierarchical model**


16 Lau E, Pai N, Walsh CM, Marcon M **Use and misuse of IV pantoprazole in paediatric inpatients**

17 Raj P, Soon JA, Shoveller J **Using GIS maps to interpret patterns of contraceptive use among youth across British Columbia**

---

**POSTER PRESENTATIONS**

18 Seung SJ, Mittmann N **A survey of Canadian stakeholders about OctreoScan utilization**

19 Seung SJ, Mittmann N, Sharma M, and The BURST Study Investigators **Resource use after an ischemic stroke: results from The BURST Study**

20 Dolovich L, Levine M, Holbrook A, Thabane L, Nair K, Riemersma K **A systematic review of interventions that optimize medication prescribing and use in Canada**


23 Chan BCF, McLean D, Bell M, Shear NH, Bell H, Mittmann N **One-year drug retention in etanercept patient support program enrollees**
24 Ferrusi IL, Marshall DA, Earle C, Trudeau M, Leighl NB, Pullenayegum E How are breast cancer testing practices for personalised medicine documented in Ontario? A retrospective review of coded surgical pathology reports

25 Marra F, Kacorzowski JA, Marra CA Assessing pharmacists’ preparedness for delivering the pandemic influenza vaccine in B.C.

26 Rance L, Hwang P Association of co-payments with compliance and employee sick days/short-term disability (ACCESS): a real-world, randomized study


28 Thorne C, Cividino A, Widdifield J, Paterson M, Pope J, Bernatsky S, Li X, Ashoor H, Cesta A, Bombardier C Baseline characteristics & preliminary efficacy results of patients receiving biologic and traditional disease modifying anti-rheumatic drugs (DMARDs) in Ontario: results from the OBRI


31 Petrella R, Mak D, Ferrazzi S, Kleinstiver P Chronic obstructive pulmonary disease (COPD) prevalence, disease severity, related healthcare resource utilization in Southwestern Ontario

32 Hopkins M, Brownrigg R, Magner P Conversion from epoeitin alfa to darbepoietin alfa may be cost-saving in Canadian dialysis patients

33 Grima D, Mendelssohn D, Airia P, Dunn E, Bernard L Cost-effectiveness analysis of sevelamer for the treatment of hyperphosphatemia in older Canadian patients with end-stage renal disease

34 Kamdeu Fansi AA, Guertin JR, Li G, Harasymowycz PJ, Rhame E, LeLorier J Cost-effectiveness of different modes of screening for open angle glaucoma in glaucoma high-risk populations

35 Kröger E, van Marum R, Souverein P, Egberts T Discontinuation of cholinesterase inhibitors: an administrative database study from the Netherlands

36 – ENCORE PRESENTATION
Deal K, Marshall DA, Dabrowski D, Ciobanu A, Bukoski M, Moayyeddi P *Discrete choice experiment to determine willingness-to-pay for gastroesophageal reflux disease (GERD) treatment*

Isogai P, Cheung M, Mittmann N *Economic analysis of alemtuzumab in fludarabine-refractory and relapsed chronic lymphocytic leukemia in Canada*


O’Reilly D, Blackhouse G, El-Hadi W, Goeree R *Using the Cardiff Long Term Model to estimate the long-term cost-utility of adding Onglyza™ (saxagliptin) versus a thiazolidinedione (TZD) in patients with type 2 diabetes mellitus (T2DM) with insufficient glycemic control using maximal doses of metformin monotherapy and after failure or contraindication to sulfonylurea combination therapy.*

Paradis PE, Carter V, Mishagina N, Raymond V *Economic impact of delays in listing decisions by provincial drug plans following a positive Common Drug Review recommendation: the case of a smoking cessation treatment (varenicline)*

Cowan CD, Po P, Abdallah M *Effect of a two-tier formulary on prescription drug-utilization and spending: evidence from Canadian employer-sponsored drug plans*

**ENCORE PRESENTATION**


Forte L, Hughes E *Funding IVF for infertile Canadians: a cost-effectiveness analysis*

**WITHDRAWN**

Simonyi S, Jog M, Beauchamp R, Miller R, Bhogal M, Wein T *Impact of botulinum toxin type a (BOTOX®) on health utility in patients receiving treatment for approved therapeutic indications: baseline characteristics and interim results of a large ongoing phase iv prospective observational cohort study (MDs on BOTOX® utility-mobility) in Canada*


Taylor DW, MacLeod SM, Rieder M, Turgeon J, Ridgway A, Thorpe R, Thomas A, Veenhuizen MF, West A *Key learning points for physicians, pharmacists and patient groups from a clinical roundtable on subsequent entry biologics*

Street C, Hodgkinson K, Perrot-Daley A, Sturje M, Young T, West R, Rahman P, Pullman D *Knowledge of your family history could save your life – using information technology to link genealogical information to prevent sudden cardiac death*
49 Longo CJ Out-of-pocket costs for cancer related drugs: effects of multiple health services deductibles on perceived patient burden in Ontario

50 Cunningham CM, Hanley GE, Morgan SG Patterns in the use of benzodiazepines in British Columbia: Examining the impact of increasing research and guideline cautions against long-term use

51 Marshall DA, Ferrusi IL, Kulin NA, Phillips KA Personalized medicine and the translation of research into practice

52 Lessard M, Roy L, Dragomir A, Perreault S Population-based study: impact of adherence level of antihypertensive agents on onset of end-stage renal disease

53 Tremblay E, Gaudet M Prevalence of potentially inappropriate prescriptions (PIPs) in Québec's elderly population, 2000-2006


55 Sproule J, Jonsson E, Chuck A Prioritizing research in evaluation


59 Gagnon E Release of pharmaceuticals into the environment by consumers: a Canadian perspective

60 Costa-Scharplatz M, Jensen MM, Liovas A Long-term cost-effectiveness of rosvuastatin compared with generic atorvastatin in a Canadian health care setting

61 Folia C, Liovas A Review of studies evaluating the impact of policy-driven statin switch programs on patients
62 Gamble JM, Eurich DT, Ezekowitz JA, Kaul P, Hude Q, McAlister FA *Sex differences in one-year mortality in people with heart failure among urban and rural residences in Alberta, Canada*


64 Tarride J-E, Haq M, O’Reilly D, Bischof M, Xie F, Bowen J, Blackhouse G, Goeree R *The burden of rheumatoid-arthritis in Ontario*

65 – ENCORE PRESENTATION
Najafzadeh M, Marra CA, Lynd LD, Sadatsafavi M, Sin DD *The economic value of a potential biomarker for chronic obstructive pulmonary disease*


67 Guénette L, Gaudet M, Tremblay É *The use of lipid-lowering drugs in Québec from 2004 to 2008: a cohort study*

68 Metge CJ, Azimee M, Lix L, Morin S, Caetano P, Leslie WD *Using cost-of-illness analysis to describe the direct burden of fracture: estimates of potential savings from prevention*

69 Singh S, Belanger D, Cameron C *Using mixed treatment comparisons to generate recommendations for optimal use of medications*

70 Dragomir A, Angers J-F, Tarride J-E, Rouleau G, Drapeau P, Perreault S *Validation of a Monte-Carlo Markov model for schizophrenia*

71 Marin-Leblanc M, Perreault S, Dubé MP *Validation of warfarin pharmacogenetic algorithms in real clinical practice: preliminary results*

72 Smith LM, Lévesque LE, Nasr M, Perry AG *Validity of the immunization record information system (IRIS) database for epidemiologic studies of the human papillomavirus (HPV) vaccine*

73 Holbrook AM, Dua M, Nikitovic M, Troyan S, Pulleneyagum E, Crowther M *Will individualized benefit-harm risk information affect patients’ decisions regarding warfarin*
THANK YOU TO OUR SPONSORS FOR YOUR SUPPORT

PLATINUM

AMGEN
AstraZeneca
GlaxoSmithKline

MERCK
Pfizer
Sanofi Aventis

Takeda

GOLD

Lilly
Innovus

SILVER

AXIA Research
Bayer
Cornerstone Research Group

Genzyme
Roche

Novartis
Novo Nordisk

SERVIER

BRONZE

Oxford Outcomes
Pharmides
Purdue